ES2065907T3 - Procedimiento para la produccion de un peptido fisiologicamente activo que contiene un resto cisteina. - Google Patents

Procedimiento para la produccion de un peptido fisiologicamente activo que contiene un resto cisteina.

Info

Publication number
ES2065907T3
ES2065907T3 ES88301924T ES88301924T ES2065907T3 ES 2065907 T3 ES2065907 T3 ES 2065907T3 ES 88301924 T ES88301924 T ES 88301924T ES 88301924 T ES88301924 T ES 88301924T ES 2065907 T3 ES2065907 T3 ES 2065907T3
Authority
ES
Spain
Prior art keywords
amino acid
target peptide
fusion protein
terminal
linker amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88301924T
Other languages
English (en)
Inventor
Koji Magota
Takehiro Oshima
Shoji Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2065907T3 publication Critical patent/ES2065907T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN PROCESO PARA LA PRODUCCION DE UN PEPTIDO FISIOLOGICAMENTE ACTIVO (PEPTIDO DIANA) QUE CONTIENE UN RESIDUO DE CISTEINA, Y COMPRENDE LAS ETAPAS DE: 1) CULTIVAR ESCHERICHIA COLI TRANSFORMADO CON UN PLASMIDO CAPAZ DE EXPRESAR UNA PROTEINA DE FUSION, BAJO CONTROL DE UN PROMOTOR DE ORIGEN DE E.COLI O UN PROMOTOR DE UN ORIGEN DE FASE, DONDE LA PROTEINA DE FUSION ESTA REPRESENTADA POR LA FORMULA A-L-B, SIENDO B EL PEPTIDO DIANA QUE CONTIENE EL RESIDUO DE CISTEINA, A ES UN POLIPEPTIDO ACOMPAÑANTE QUIE CONTIENE DE 90 A 220 RESIDUOS DE AMINOACIDOS PERO NO DE CISTEINAL Y L REPRESENTA UN ENLAZADOR DE RESIDUOS DE AMINOACIDOS SITUADO ENTRE EL C TERMINAL DEL POLIPEPTIDO ACOMPAÑANTE Y EL N-TERMINAL DEL PEPTIDO DIANA; 2) DISOCIAR LAS CELULAS CULTIVADAS Y OBTENER UNA FRACCION INSOLUBLE QUE CONTIENE LA PROTEINA DE FUSION;Y 3) SOLUBILIZAR LA PROTEINA DE FUSION CON UN AGENTE SOLUBILIZANTE, Y TRATAR ELPRODUCTO SOLUBILIZADO CON UNA PROTEASA O UNA SUSTANCIA QUIMICA PARA LIBERAR Y AISLAR EL PEPTIDO DIANA.
ES88301924T 1987-03-04 1988-03-04 Procedimiento para la produccion de un peptido fisiologicamente activo que contiene un resto cisteina. Expired - Lifetime ES2065907T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4779687 1987-03-04

Publications (1)

Publication Number Publication Date
ES2065907T3 true ES2065907T3 (es) 1995-03-01

Family

ID=12785332

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88301924T Expired - Lifetime ES2065907T3 (es) 1987-03-04 1988-03-04 Procedimiento para la produccion de un peptido fisiologicamente activo que contiene un resto cisteina.

Country Status (11)

Country Link
US (1) US4987070A (es)
EP (1) EP0281418B1 (es)
JP (1) JPH0687788B2 (es)
AT (1) ATE117023T1 (es)
AU (1) AU607973B2 (es)
CA (1) CA1340830C (es)
DE (1) DE3852706T2 (es)
DK (1) DK175535B1 (es)
ES (1) ES2065907T3 (es)
GR (1) GR3015328T3 (es)
HU (1) HU210625B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3686365T3 (de) * 1985-06-20 2000-07-27 Fujisawa Pharmaceutical Co., Ltd. Herstellungsverfahren für humanes atriales natriuretisches Polypeptid.
DE3805150A1 (de) * 1987-04-11 1988-10-20 Hoechst Ag Gentechnologisches verfahren zur herstellung von polypeptiden
DE3716722A1 (de) * 1987-05-19 1988-12-01 Hoechst Ag Gentechnologisches verfahren zur herstellung von angiogeninen
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
JP2535398B2 (ja) * 1989-01-17 1996-09-18 サントリー株式会社 アミド化ペプチドの製造方法
CA2051375C (en) * 1989-05-04 2000-09-12 Dennis J. Henner Process and compositions for the isolation of human relaxin
US5202239A (en) * 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
US6077694A (en) * 1990-09-21 2000-06-20 The United States Of America As Represented By The Department Of Health And Human Services Method for over-expression and rapid purification of biosynthetic proteins
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
ATE253639T1 (de) * 1991-08-19 2003-11-15 Daiichi Suntory Pharma Co Ltd Verfahren zur herstellung von peptiden
JP3531947B2 (ja) * 1991-08-19 2004-05-31 第一サントリーファーマ株式会社 ペプチドの製造方法
US5795776A (en) * 1994-03-22 1998-08-18 Bio-Technology General Corp. Expression plasmids regulated by an OSMB promoter
WO1997023639A1 (en) * 1995-12-22 1997-07-03 Toray Industries, Inc. Process for producing biologically active fused proteins
DE69930938T2 (de) * 1998-07-10 2007-01-11 Scios Inc., Fremont Verfahren zur herstellung eines peptids mit einem pi grösser als 8 oder kleiner als 5
US6818611B1 (en) * 1998-10-13 2004-11-16 University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
AU783954B2 (en) 2000-05-10 2006-01-05 Asubio Pharma Co., Ltd. Method of inhibiting the formation of by-product in the production of genetically modified polypeptide
JP4088584B2 (ja) * 2001-07-26 2008-05-21 アドバンスド プロテイン テクノロジーズ コーポレイション 融合タンパク質から目的タンパク質を分離する方法。
CN1298742C (zh) * 2003-06-03 2007-02-07 上海新药研究开发中心 一种适合于高效表达的融合蛋白及其生产方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527165B2 (en) * 1977-02-08 1983-02-17 Genentech Inc. Method and means for microbial polypeptide expression; synthetic DNA and process therefor
NO158880C (no) * 1977-11-08 1988-11-09 Genentech Inc Fremgangsmaate for fremstilling av et spesifikt pattedyrhormon.
NL7811040A (nl) * 1977-11-08 1979-05-10 Genentech Inc Synthetische dna en werkwijze ter bereiding daarvan.
US4431739A (en) * 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
CA1200773A (en) * 1980-02-29 1986-02-18 William J. Rutter Expression linkers
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
JPS5869897A (ja) * 1981-10-20 1983-04-26 Gakuzo Tamura Ｄｎａ遺伝子
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
SE8300693L (sv) * 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
US4711844A (en) * 1983-03-09 1987-12-08 Cetus Corporation Modified signal peptides
GB8308483D0 (en) * 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
GB2140810B (en) * 1983-05-24 1987-07-08 Celltech Ltd Polypeptide and protein products, and process for their production
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4549986A (en) * 1983-12-23 1985-10-29 The Salk Institute For Biological Studies Human CGRP
US4736023A (en) * 1983-12-23 1988-04-05 The Salk Institute For Biological Studies DNA encoding human CGRP
JPH0672155B2 (ja) * 1984-08-24 1994-09-14 塩野義製薬株式会社 α−ｈＡＮＰ抗血清作製用ポリペプチド
DE3686365T3 (de) * 1985-06-20 2000-07-27 Fujisawa Pharmaceutical Co., Ltd. Herstellungsverfahren für humanes atriales natriuretisches Polypeptid.
GB8515686D0 (en) 1985-06-20 1985-07-24 Fujisawa Pharmaceutical Co Production of-human atrial natriuretic polypeptide
GB8600754D0 (en) 1986-01-14 1986-02-19 Fujisawa Pharmaceutical Co Human atrial natriuretic polypeptide
US4743679A (en) * 1986-02-24 1988-05-10 Creative Biomolecules, Inc. Process for producing human epidermal growth factor and analogs thereof
DE3805150A1 (de) * 1987-04-11 1988-10-20 Hoechst Ag Gentechnologisches verfahren zur herstellung von polypeptiden

Also Published As

Publication number Publication date
DK175535B1 (da) 2004-11-29
ATE117023T1 (de) 1995-01-15
HUT46071A (en) 1988-09-28
AU607973B2 (en) 1991-03-21
HU210625B (en) 1995-06-28
DK114788A (da) 1988-09-05
EP0281418B1 (en) 1995-01-11
US4987070A (en) 1991-01-22
GR3015328T3 (en) 1995-06-30
EP0281418A3 (en) 1989-04-26
DE3852706T2 (de) 1995-05-24
CA1340830C (en) 1999-11-30
EP0281418A2 (en) 1988-09-07
AU1272488A (en) 1988-09-15
DE3852706D1 (de) 1995-02-23
JPS6410999A (en) 1989-01-13
DK114788D0 (da) 1988-03-03
JPH0687788B2 (ja) 1994-11-09

Similar Documents

Publication Publication Date Title
ES2065907T3 (es) Procedimiento para la produccion de un peptido fisiologicamente activo que contiene un resto cisteina.
Kurosky et al. Primary structure of cholera toxin β-chain: A glycoprotein hormone analog?
NZ232742A (en) Yeast heterologous protein production method, vectors, dna constructs and proteins so produced and aprotinin (1-58) so produced
ATE80166T1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
ZA856194B (en) Method of removing n-terminal amino acid residues from eucaryotic polypeptide analogs and polypeptides produced thereby
EP0528686B8 (en) Process for producing peptides
EP0210279A4 (en) Stabilized human prourokinase.
DK0446315T3 (da) Fremgangsmåde til fremstilling af PAI-2
EP0330700A4 (en) Human prourokinase-like polypeptide.
CA2198966A1 (en) Method for cleaving chimeric protein using processing enzyme
Ishizaki et al. Production of recombinant human glucagon in the form of a fusion protein in Escherichia coli; recovery of glucagon by sequence-specific digestion
Salokangas et al. Bovine proinsulin: amino acid sequence of the C‐peptide isolated from pancreas
BOTTI JR et al. IDENTIFICATION OF AN ATP-ACTIVATED ENDOPEPTIDASE FROM RAT KIDNEY WHICH CATALYZES CLEAVAGE OF PARATHYROID HORMONE TO FRAGMENTS IDENTICAL TO THOSE PRODUCED IN THE RAT KIDNEY in vivo1
Chretien et al. Processing of peptide hormone and neuropeptide precursors
KR910700345A (ko) 사람 갑상선 기원의 재조합 C-말단 α-아미드화 효소
Bonic et al. Expression, purification, and PC1-mediated processing of human proglucagon, glicentin, and major proglucagon fragment
Mills et al. Fragments of human growth hormone produced by digestion with bromelain: Chemistry and biological properties
BRANDAU et al. New bovine adrenal medullary peptide and its precursor
Ten et al. Metabolites of the pathogenic fungus Verticillium dahliae. XI. Primary structure of the polypeptide moiety of the phytotoxic pigment PKZh-1

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 281418

Country of ref document: ES